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Summary
Background Although advances in the treatment of myeloid neoplasms have led to improved patient survival, this 
improvement has been accompanied by an increased risk of second primary cancer (ie, the risk of another cancer 
after myeloid neoplasia). We aimed to assess bi-directional associations between myeloid cancers and other cancers—
ie, development of second primary cancer in patients who have previously had myeloid cancer, and risks of myeloid 
neoplasia in patients who have previously had another cancer—to provide insight into possible mechanisms beyond 
side-effects of treatment and shared risk factors. 
Methods Using the Swedish Family-Cancer Database, we identified 35 928 individuals with primary myeloid cancer, 
including myeloproliferative neoplasms, acute myeloid leukaemia, chronic myeloid leukaemia, and myelodysplastic 
syndrome diagnosed between 1958 and 2015. The Swedish Family-Cancer Database includes every individual 
registered as a resident in Sweden starting in 1932, with full parental history. The primary endpoint was the 
assessment of relative risks (RRs) for second primary cancer, which we performed using means of incidence rate 
ratios, regressed over a generalised Poisson model.
Findings Between 1958 and 2015, overall relative risk of second primary cancers was significantly increased after acute 
myeloid leukaemia (RR 1·29, 95% CI 1·17–1·41), chronic myeloid leukaemia (1·52, 1·35–1·69), myelodysplastic 
syndrome (1·42, 1·26–1·59), and all myeloproliferative neoplasms (1·37, 1·30–1·43) relative to the incidence of these 
cancers as first primary cancer. With myeloid neoplasia as a second primary cancer, risks were significantly increased 
for acute myeloid leukaemia (1·57, 1·48–1·65), chronic myeloid leukaemia (1·26, 1·13–1·40), and myelodysplastic 
syndrome (1·54, 1·42–1·67) relative to the incidence of these myeloid neoplasms as first primary cancers. Relative 
risk of upper aerodigestive tract cancer, squamous cell skin cancer, and non-Hodgkin lymphoma as second primary 
cancers were increased after all four types of myeloid neoplasia relative to their incidence as first primary cancers. 
High risks of myelodysplastic syndrome and acute myeloid leukaemia as second primary cancers were found after 
haematological cancers (RRs between 5·08 and 10·04).
Interpretation The relative risks of second primary cancer are important for the long-term management of patients 
with myeloid cancers. The bi-directional associations of myeloid cancers with many other cancers suggest a number 
of candidate mechanisms that might contribute to the development and aetiology of a second primary cancer. These 
mechanisms might include immune dysfunction or the effects of treatment, and these should be assessed in future 
investigations.
Funding Deutsche Krebshilfe, Jane and Aatos Erkko Foundation, Sigrid Juselius Foundation, Finnish Cancer 
Organizations, Swedish Research Council, ALF from Region Skåne, and Bloodwise.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Introduction
All myeloid cancers originate from the same haemopoietic 
lineage and are characterised by excessive proliferation, 
abnormal self-renewal, and differentiation defects.1,2 
The distinct clinical phenotypes are BCR-ABL1-negative 
myeloproliferative neoplasms, polycythaemia vera, essen- 
tial thrombocythemia, myelofibrosis, chronic myeloid 
leukaemia, myelodysplastic syndrome, and acute myeloid 
leukaemia. Polycythaemia vera is char acterised by a 
high erythrocyte count, essential thrombocythaemia by a 
high platelet count, and myelofibrosis by bone marrow 
failure. Myelodysplastic syndrome is characterised by 
ineffective haemopoiesis, morphological dysplasia in 
haemopoietic cells, and cytopenia.3 Although myelopro- 
liferative neoplasm sub types are independent diseases, 
transformation from myeloproliferative disorders and 
myelodysplastic syn drome to acute myeloid leukaemia 
can occur.2,4
The causes of myeloid diseases are poorly understood 
and few risk factors have been identified. Known risk 
factors for acute myeloid leukaemia include exposure 
to ionising radiation, chemicals such as benzene, and 
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cytotoxic chemotherapy.2 For myelodysplastic syndrome 
risk factors include autoimmune disorders and immuno- 
logical aber rations.5–7 Several rare high penetrance mu- 
tations in cancer susceptibility genes—such as Janus 
kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative 
leukaemia virus oncogene (MPL)—have been identified 
and are now incorporated in disease classification, for 
example for myeloproliferative neoplasms.3,8 Treatment for 
myelopro liferative disorders aims to reduce the risk of 
progression and has relied on compounds such as 
hydroxyurea, inhibiting DNA synthesis, and cytokine 
interferon alpha, which modulates immune and other 
functions; more recently specific JAK-2 inhibitors have 
been included in treatment.9 Patients with acute myeloid 
leukaemia might receive induction treatment with DNA 
synthesis inhibitors, such as cytarabine and anthracycline, 
supple mented with hydroxyurea. Consolidation treatment 
could include cytarabine administration or bone marrow 
transplantation. Until tyrosine kinase inhibitors were 
introduced into the standard of care for BCR-ABL1-positive 
patients in about the year 2000, treatment for chronic 
myeloid leukaemia was hydroxycarbamide, interferon 
alpha, and allogeneic haemopoietic stem-cell trans-
plantation, and still remains the standard treatment.10 
Treatment options for myelodysplastic syndrome, which 
depend on diagnostic findings and symptoms, can include 
multiple modalities. Treatment for first cancers might be 
an important risk factor for second primary cancers. 
Recent advances in the management of all forms of 
myeloid cancers, including personalised approaches, 
have greatly improved patient survival. However, this 
increase in survival has been accompanied by an increase 
in the number of second primary cancers and other 
treatment-related complications, such as cardiovascular 
and neurological symptoms.11 Several studies have 
estimated the risks of second primary cancers after 
myeloid cancer, but most have confined their analyses to 
acute myeloid leukaemia and chronic myeloid leukaemia, 
with scant available data for myeloproliferative neo- 
plasms.9,12–15 This gap in the literature seems to be largely 
because most cancer registries do not collect data on 
other myeloid cancers. To address this deficiency, we 
used data from the Swedish Cancer Registry to analyse 
all myeloid cancers and second primary cancers after 
myeloid cancers in Sweden, and myeloid cancers 
diagnosed as second primary cancers following the 
occurrence of any non-myeloid first cancer.
Methods
Study design and participants
The Swedish Family-Cancer Database includes data from 
the Swedish population, organised by families, and linked 
to the national Cancer Registry. The registry relies on 
compulsory notifications from clinicians who diagnose 
any neoplasm and separate notifications from pathologists 
and cytologists. It includes every individual registered as 
a resident in Sweden since 1932 with full parental 
histories. The database’s coverage is estimated at more 
than 90% of all cancer diagnoses in Sweden, with more 
than 2 million cancers registered since 1958.16 The registry 
counts tumours not patients, except in cases where a 
patient has more than one tumour of the skin or urinary 
tract diagnosed in the same topological area. To classify 
cancer types, the Swedish Cancer Registry has used 
International Classification of Disease (ICD)-7 since 1958, 
ICD-9 since 1987, SNOMED (ICD-O/2) since 1993, and 
ICD-O/3 since 2005. The degree of histological 
verification of myeloid cancers varies from 98% to 
Research in context
Evidence before this study
We searched PubMed with the search terms “second primary 
cancer after myeloid disease” and “myeloid disease diagnosed 
after cancer”; we also applied specific myeloid diseases as search 
terms. Furthermore, we reviewed the literature cited in the 
identified papers. 
Added value of this study
The present study applied two novel approaches. Using data 
from 35 928 individuals with myeloid neoplasia registered with 
the Swedish Cancer Registry, we analysed risk of second primary 
cancer after all main types of primary myeloid cancer, including 
myelodysplastic syndrome, which had not previously been 
assessed in the context of relative risk for second primary 
cancer. Furthermore, we used bi-directional analysis to assess 
risk of second primary cancers after myeloid neoplasms, and 
risk of myeloid neoplasms after any of 32 cancers. Our findings 
showed that risks of myeloid neoplasms were associated with 
all haematological cancers. We showed that the increased risk 
of second primary cancers is not confined to a specific myeloid 
cancer, and that it is also increased after myelodysplastic 
syndrome. Bi-directional increases in risk were observed for 
nine myeloid neoplasia-cancer pairs. Upper aerodigestive tract 
cancer, squamous cell skin cancer, and non-Hodgkin lymphoma 
were the major second primary cancers following diagnosis of 
acute myeloid leukaemia, chronic myeloid leukaemia, 
myelodysplastic syndrome, and myeloproliferative neoplasm. 
The results suggest that new mechanisms, such as immune 
dysfunction, might contribute to bi-directional risks. 
Implications of all available evidence
Increased risks of myeloid cancers after melanoma, squamous 
cell skin cancer, and kidney cancers, all of which are treated 
mainly by surgery, raise the possibility that immune 
dysfunction could be a contributing factor to second primary 
cancers in people who have had myeloid cancer, but this 
hypothesis requires further studies. Treatment for myeloid 
neoplasms has undergone many recent changes and 
therapeutic successes need to be weighed against side-effects, 
such as risk of second primary cancer.
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100% for acute myeloid leukaemia and chronic myeloid 
leukaemia, to about 95% for polycythaemia vera and 
myelofibrosis.17 An ad hoc study of the diagnostic accuracy 
of second neoplasms in the Swedish Cancer Registry 
found 98% of these to be correctly classified; no recorded 
second primary cancer was found to be a metastasis upon 
re-examination.18
The Swedish Cancer Registry organises reported cancers 
as first, second, third primary cancer, and so on, and we 
followed this order. We included data from all patients 
whose first primary cancer was acute myeloid leukaemia, 
chronic myeloid leukaemia, myelodysplastic syndrome, 
polycythaemia vera, essential thrombo cythaemia, myelo- 
fibrosis, or myeloproliferative neoplasm (not otherwise 
specified) diagnosed between 1958 and 2015, and were 
analysed for the relative risk of second primary cancer. In 
assessing the relative risk of myeloid cancers as a second 
primary cancer, we included patients with any first primary 
cancer except leukaemia, to avoid dependency. We selected 
any of 32 cancers by the main categories of ICD-7. We used 
ICD-7 and ICD-O/2 codes to distinguish between different 
haematological cancers and subtypes. Myeloproliferative 
neoplasms were classified according to the 2016 WHO 
classification. Myeloproliferative neoplasm (not other wise 
specified), myelofibrosis, and myelodysplastic syndrome 
were distinguished in ICD-O/2, and included as distinct 
entities in the database from 1993. We excluded rare 
myeloproliferative neoplasms, such as chronic eosinophilic 
leukaemia and chronic neutrophilic leukaemia, from our 
subtype analysis. We did not include data from patients 
who developed myeloid disease after previous myeloid 
disease because of the potential for transformation 
between tumour types. The ICD codes used by the Swedish 
Cancer Registry do not specify treatment-related cancers, 
although the literature suggests that treatment-related 
cancers now account for 7% of acute myeloid leukaemia.19 
The study periods were constrained by the availability of 
data. 
Outcomes and statistical analysis
Relative risks (RRs) for second primary cancers were 
assessed by means of incidence rate ratios, assuming that 
cancer diagnoses followed waiting time distribution, 
regressed over a fixed effects generalised Poisson model. 
Regression was assessed on case numbers scaled on 
person-years. This reduced case numbers as compared 
with the reference fractions in each person-year category. 
Person-year calculation for the background population 
ensured large case numbers in each covariate band and 
met the large number assumption for the Poisson 
distribution. RRs for the second primary cancer were 
obtained by comparing incidence of that cancer type in 
the general Swedish population without previous 
diagnosis of cancer with the incidence of that cancer type 
as a second primary cancer in patients who had had 
myeloid cancer as a first primary cancer. Conversely, to 
consider myeloid cancers as second primary cancers, the 
incidence rates were compared against the incidence of 
the first primary myeloid neoplasm in the background 
population without a previous cancer diagnosis. These 
two types of analyses constituted the bi-directional or 
reciprocal analyses. Sex, age group, calendar-period, socio-
economic status, and residential area were regarded as 
potential confounders and were adjusted for in the 
regression model. Confidence intervals (CIs) were 
calculated for 5%, 1% and 0·1% level of significance.
All analyses were done with SAS (version 9.4) or 
R (version 3.3.4). The study was approved by the Ethical 
Committee of Lund University, Sweden, and conducted 
in accordance with the Declaration of Helsinki.
First primary cancer Any second primary 
cancer*
Median follow up 
(years)
Sex
Men 18 816 (52·4%) 1405 (53·4%) ··
Women 17 112 (47·6%) 1226 (46·6%) ··
Year
1958–70 8334 132 (5·0%) ··
1971–85 7775 542 (20·6%) ··
1986–2000 8551 923 (35·1%) ··
2001–15 11 268 1034 (39·3%) ··
First primary cancer 
Acute myeloid leukaemia 12 832 427 (3·3%) 3 (2–5)
Chronic myeloid leukaemia 5567 306 (5·5%) 3 (2–6)
Myelodysplastic syndrome 3520 259 (7·4%) 1 (0–5)
Polycythemia vera 6636 916 (13·8%) 6 (3–9)
Essential thrombocythaemia 4081 422 (10·3%) 4 (3–10)
Myelofibrosis 1454 118 (8·1%) 2 (0–5)
Chronic neutrophilic leukaemia or 
chronic eosinophilic leukaemia
204 10 (4·9%) 2 (0–3)
Myeloproliferative neoplasm 
(not otherwise specified)
1634 173 (10·6%) 3 (1–6)
Data are n (%) or median (IQR). *Second primary cancers after primary myeloid cancers.





Acute myeloid leukaemia 1463 (37·7%) 5 (2–11)
Chronic myeloid leukaemia 380 (9·8%) 6 (3–13)
Myelodysplastic syndrome 750 (19·4%) 6 (3–11)
Polycythaemia vera 474 (12·2%) 8 (3–15)
Essential thrombocythaemia 392 (10·1%) 10 (3–18)
Myelofibrosis 171 (4·4%) 6 (2–14)
Chronic neutrophilic leukaemia 
or chronic eosinophilic 
leukaemia
22 (0·6%) 10 (5–14)
Myeloproliferative neoplasm 
(not otherwise specified)
221 (5·7%) 5 (2–13)
Data are n (%) or median (IQR). Follow-up time is the duration of follow up 
between diagnosis of first primary cancer and diagnosis of second primary cancer.
Table 2: Patients with myeloid cancer as a second primary cancer
For more on Survey of Nordic 
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Role of the funding source
The funders had no role in the design or conduct of the 
study. KH had full access to all the data in the study and 
had final responsibility for the decision to submit for 
publication.
Results
Of the 35 928 patients recorded by the Swedish Cancer 
Registry with primary myeloid cancer between 1958 and 
2015, 1405 men and 1226 women developed a second 
primary cancer with a median follow up of 4 years 
(table 1). Acute myeloid leukaemia was the most common 
primary myeloid cancer (12 832 patients), but only 
427 (3%) were diagnosed with a second primary cancer. 
Of 6636 patients with polycythemia vera, 916 (14%) were 
diagnosed with a second primary cancer (table 1). Of the 
940 811 other patients, 3873 (<1%) developed a myeloid 
cancer as a second primary cancer (table 2), with a 
median follow up of 6 years.
We did stratified risk analyses on second primary cancer 
incidence after myeloid neoplasia, stratifying by time, sex, 
age at first cancer diagnosis, and duration of follow up 
between diagnosis of first primary cancer and diagnosis of 
second primary cancer (appendix pp 2–5). No cases with 
myelodysplastic syndrome or myeloproliferative neoplasm 
(not otherwise specified) were recorded in the early study 
periods, as the coding system for identification of these 
cases started to be used in 1993 (appendix p 2). RRs for the 
second primary cancer did not differ between study 
periods (ie, 95% CIs were overlapping), with the exception 
of a high RR of 1·81 for myeloproliferative neoplasm 
between 1971 and 1985, partly caused by the high RR for 
essential thrombo cythaemia. Sex did not affect risk for 
second primary cancer (appendix p 3) but diagnosis with 
myeloid neoplasia below the age of 65 years was a strong 
risk modifier (increased risk), except in patients with 
myelodysplastic syndrome (appendix p 4). Follow-up time 
between diagnosis of first primary cancer and diagnosis of 
second primary cancer did not systematically affect risk of 
developing a second primary cancer; we noted significantly 
increased risks of a second primary cancer after myeloid 
neoplasia in most follow-up periods (appendix p 5). For all 
patients with myelo dysplastic syndrome, maximal follow 
up was relatively short at 30 years (ie, 1986–2015). We 
analysed relative risks of a second primary cancer after 
chronic myeloid leukaemia in more detail, because 
standard treatment for chronic myeloid leukaemia 
changed with the introduction of tyrosine kinase inhibitors 
around the year 2000 (appendix p 6). Although few second 
primary cancers were recorded in this analysis, we noted 
significant increases in the risk of upper aerodigestive 
tract, thyroid, and connective tissue cancers as second 
primary cancers in the period between 2001 and 2015 
relative to the background risk of these cancers as first 
primaries between 2001 and 2005.
Table 3 shows the RRs of a second primary cancer 
after a myeloid cancer, and of myeloid cancer as a 
second primary cancer. Overall, the relative risk of second 
primary cancer after all myeloid cancers was increased 
1·36 (95% CI 1·30–1·42) times relative to the background 
risk of any first primary cancer diagnosis. An increased 
risk was shown for 15 cancer sites, notably for nasal 
cancer (RR 3·10, 95% CI 1·61–5·97), squamous cell skin 
cancer (2·80, 2·50–3·14), and Hodgkin lymphoma 
(2·63, 1·59–4·37). These RRs were significant at the 
0·1% level. Myeloid cancer as a second primary cancer 
showed an RR of 1·32 (95% CI 1·28–1·37). Individually, 
Relative risk of second primary cancer 
after myeloid neoplasia
Relative risk of myeloid neoplasia as 
second primary cancer
N RR CI Lower CI Upper N RR CI Lower CI Upper
Upper aerodigestive 
tract
77 1·95* 1·56 2·43 94 1·15 0·94 1·40
Oesophagus 26 1·38 0·95 2·00 6 0·75 0·34 1·66
Stomach 75 0·93 0·74 1·17 66 1·00 0·79 1·27
Small intestine 15 1·71† 1·03 2·84 17 1·66† 1·03 2·67
Colorectum 248 0·97 0·86 1·10 362 1·06 0·95 1·17
Anus 9 2·31‡ 1·24 4·30 8 1·37 0·69 2·75
Liver 76 1·21 0·96 1·52 8 0·47† 0·24 0·94
Pancreas 64 1·04 0·82 1·33 7 0·45† 0·21 0·94
Nose 8 3·10* 1·61 5·97 5 0·94 0·39 2·26
Lung 223 1·40* 1·23 1·60 73 1·11 0·88 1·39
Breast 184 0·98 0·84 1·13 624 1·13‡ 1·05 1·23
Cervix 12 0·81 0·45 1·47 71 0·91 0·72 1·15
Endometrium 45 1·05 0·78 1·40 179 1·11 0·96 1·28
Ovary 36 1·12 0·80 1·55 110 1·53* 1·27 1·85
Other female genital 6 0·81 0·39 1·70 17 1·22 0·76 1·96
Prostate 419 1·05 0·96 1·16 695 1·30* 1·20 1·40
Testis 3 1·23 0·40 3·80 32 1·91* 1·35 2·70
Other male genital 2 0·58 0·14 2·31 6 0·78 0·35 1·73
Kidney 107 2·07* 1·71 2·51 112 1·54* 1·28 1·85
Bladder 126 1·31‡ 1·10 1·56 237 1·40* 1·23 1·59
Melanoma 104 1·84* 1·52 2·23 169 1·27‡ 1·09 1·47
Skin SCC 301 2·80* 2·50 3·14 195 1·47* 1·28 1·70
Eye 4 0·72 0·23 2·25 15 1·33 0·80 2·21
Nervous system 90 2·23* 1·82 2·73 88 1·12 0·91 1·38
Thyroid gland 14 1·42 0·86 2·36 73 2·06* 1·64 2·59
Endocrine gland 51 2·24* 1·71 2·94 100 1·25† 1·03 1·52
Bone 4 2·14 0·80 5·70 9 1·50 0·78 2·88
Connective tissue 21 1·99‡ 1·30 3·05 29 1·47† 1·02 2·11
Non-Hodgkin 
lymphoma
119 1·95* 1·62 2·34 239 3·31* 2·91 3·76
Hodgkin’s 
lymphoma
15 2·63* 1·59 4·37 59 4·47* 3·46 5·77
Multiple myeloma 49 1·60* 1·21 2·12 122 4·78* 3·78 6·04
Cancer of unknown 
primary
89 1·23 1·00 1·51 26 0·98 0·67 1·45
All 2631 1·36* 1·30 1·42 3873 1·32* 1·28 1·37
N=frequency. RR=relative risk. SCC=squamous cell carcinoma. *Statistical significance at 0·1%. †Statistical significance 
at 5%. ‡Statistical significance at 1%. 
Table 3: Relative risk of second primary cancer in patients with myeloid cancer, and relative risk of 
second primary myeloid neoplasia in patients who have had other cancers
See Online for appendix
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15 cancers were associated with an increased risk of 
myeloid cancer, most notably cancers of the haema- 
topoietic system: non-Hodgkin lymphoma (RR 3·31, 
95% CI 2·91–3·76), Hodgkin’s lymphoma (4·47, 
3·46–5·77), and myeloma (4·78, 3·78–6·04). We recorded 
bi-directional increases for nine myeloid neoplasia-
cancer pairs, including cancers of the small intestine, 
kidney, bladder, skin (both melanoma and squamous cell 
carcinoma), connective tissue, and haemapoietic tissue 
(table 3).
Table 4 shows the RRs of all non-myeloid second 
primary cancers after a first diagnosis of acute myeloid 
leukaemia, chronic myeloid leukaemia, myelo dysplastic 
syndrome, or myeloproliferative neoplasm. The overall 
RRs for second primary cancers after each of these four 
diseases were 1·29 (95% CI 1·17–1·41), 1·52 (1·35–1·69), 
1·42 (1·26–1·59), and 1·37 (1·30–1·43), respectively. The 
numbers of individual non-myeloid second primary 
cancers with increased RRs were 8 for acute myeloid 
leukaemia, 7 for chronic myeloid leukaemia, 8 for 
myelodysplastic syndrome, and 12 for myeloproliferative 
neoplasm. Risk of upper aerodigestive tract cancer, skin 
squamous cell carcinoma, and non-Hodgkin lymphoma 
was increased irrespective of myeloid primary type. Risk 
of kidney cancer was increased in patients with a first 
primary cancer diagnosis of chronic myeloid leukaemia, 
myelodysplastic syndrome, and myelopro liferative neo- 
plasm relative to the background risk. For acute myeloid 
leukaemia, high RRs were noted for anal cancer 
(RR 3·92, 95% CI 1·26–12·16) and Hodgkin’s 
lymphoma (3·60, 1·35–9·60). The RR for skin squamous 
cell carcinoma was 5·54 (95% CI 4·16–7·37) after chronic 
Acute myeloid leukemia Chronic myeloid leukemia Myelodysplastic syndromes Myeloproliferative neoplasms
N RR (95% CI) N RR (95% CI) N RR (95% CI) N RR (95% CI)
Upper aerodigestive 
tract
16 2·19* (1·34–3·58) 10 2·10† (1·13–3·91) 9 2·29† (1·19–4·41) 42 1·43† (1·06–1·94)
Oesophagus 2 0·55 (0·14–2·22) 4 1·83 (0·69–4·87) 5 2·64† (1·10–6·35) 15 1·16 (1·06–1·93)
Stomach 10 0·73 (0·39–1·36) 14 1·35 (0·80–2·27) 5 1·04 (0·43–2·49) 46 0·92 (0·69–1·23)
Small intestine 2 1·25 (0·31–4·98) 2 2·07 (0·52–8·26) 2 2·12 (0·53–8·48) 9 1·50 (0·78–2·88)
Colorectum 40 0·91 (0·67–1·24) 32 1·24 (0·88–1·75) 23 0·83 (0·55–1·24) 153 0·88 (0·75–1·03)
Anus 3 3·92† (1·26–12·16) 0 ·· 1 2·02 (0·28–14·35) 5 1·71 (0·71–4·11)
Liver 20 1·82* (1·18–2·83) 6 0·87 (0·39–1·93) 5 1·09 (0·46–2·63) 45 1·14 (0·85–1·53)
Pancreas 12 1·09 (0·62–1·92) 4 0·56 (0·21–1·50) 2 0·43 (0·11–1·72) 46 1·21 (0·90–1·61)
Nose 0 ·· 1 2·75 (0·39–19·56) 2 8·14* (2·03–32·62) 5 2·51† (1·05–6·05)
Lung 36 1·26 (0·91–1·75) 18 1·06 (0·67–1·68) 30 1·99‡ (1·39–2·85) 139 1·38‡ (1·17–1·63)
Breast 31 0·88 (0·62–1·26) 13 0·60 (0·35–1·04) 9 0·61 (0·32–1·17) 131 0·98 (0·83–1·17)
Cervix 2 0·72 (0·18–2·89) 2 0·90 (0·23–3·61) 0 ·· 8 0·92 (0·46–1·85)
Endometrium 6 0·73 (0·33–1·64) 13 2·55 (1·48–4·40) 0 ·· 26 0·85 (0·58–1·25)
Ovary 10 1·60 (0·86–2·98) 2 0·45 (0·11–1·82) 2 1·11 (0·28–4·44) 22 1·04 (0·68–1·57)
Other female genital 0 ·· 0 ·· 1 1·30 (0·18–9·25) 5 0·81 (0·34–1·94)
Prostate 72 0·92 (0·73–1·15) 50 1·20 (0·91–1·58) 35 0·60† (0·43–0·84) 262 1·07 (0·95–1·21)
Testis 0 ·· 1 1·73 (0·24–12·25) 1 8·94† (1·26–63·57) 1 0·83 (0·12–5·89)
Kidney 9 0·98 (0·51–1·88) 16 2·61† (1·60–4·25) 9 2·14† (1·11–4·11) 73 2·12‡ (1·69–2·67)
Bladder 21 1·27 (0·83–1·95) 12 1·28 (0·73–2·25) 17 1·42 (0·88–2·29) 76 1·08 (0·86–1·35)
Melanoma 17 1·55 (0·96–2·49) 6 0·92 (0·42–2·06) 11 1·43 (0·79–2·59) 70 1·75‡ (1·38–2·21)
Skin SCC 37 2·18‡ (1·58–3·01) 47 5·54† (4·16–7·37) 47 2·34‡ (1·76–3·12) 170 1·94‡ (1·67–2·26)
Nervous system 22 2·69‡ (1·77–4·09) 9 1·63 (0·85–3·13) 4 1·29 (0·48–3·43) 55 2·11‡ (1·62–2·76)
Thyroid gland 3 1·56 (0·50–4·83) 3 2·23 (0·72–6·91) 0 ·· 8 1·13 (0·57–2·26)
Endocrine gland 7 1·57 (0·75–3·30) 2 0·71 (0·18–2·85) 1 0·46 (0·07–3·29) 41 2·55‡ (1·88–3·46)
Bone 1 2·68 (0·38–19·06) 0 ·· 0 ·· 3 2·59 (0·83–8·03)
Connective tissue 4 2·06 (0·77–5·48) 4 3·23† (1·21–8·60) 2 1·93 (0·48–7·70) 11 1·55 (0·86–2·80)
Non–Hodgkin 
lymphoma
18 1·67† (1·05–2·64) 14 2·27* (1·35–3·84) 22 3·17 ‡ (2·09–4·82) 65 1·60‡ (1·25–2·04)
Hodgkin lymphoma 4 3·60† (1·35–9·60) 1 1·20 (0·17–8·53) 0 ·· 10 2·77‡ (1·49–5·15)
Multiple myeloma 11 2·03† (1·13–3·67) 1 0·31 (0·04–2·17) 6 2·03 (0·91–4·51) 31 1·58† (1·11–2·25)
Cancer of unknown 
primary
7 0·54 (0·26–1·14) 15 2·00† (1·20–3·31) 7 0·97 (0·46–2·04) 60 1·31† (1·02–1·69)
All 427 1·29‡ (1·17–1·41) 306 1·52‡ (1·35–1·69) 259 1·42‡ (1·26–1·59) 1639 1·37‡ (1·30–1·43)
N=frequency; RR=relative risk. SCC=squamous cell carcinoma. *Statistical significance at 1%. †Statistical significance at 5%. ‡Statistical significance at 0·1%. 
Table 4: Relative risk of second primary cancer among survivors of myeloid cancer
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myeloid leukaemia. Myelodysplastic syndrome was 
associated with a high risk of non-Hodgkin lymphoma 
(RR 3·17, 95% CI 2·09–4·82). After a first primary cancer 
diagnosis of myeloproliferative neoplasm, the highest 
RRs were noted for Hodgkin’s lymphoma (RR 2·77, 
95% CI 1·49–5·15), followed by endocrine (2·55, 1·88–3·46), 
nasal (2·51, 1·05–6·05), kidney (2·12, 1·69–2·67), and 
nervous system (2·11, 1·62–2·73) cancers relative to the 
background risk of developing that cancer as a first 
primary cancer risk.
When comparing RRs between cancer-pairs between 
tables 4 and 5, we noted bi-directionally increased RRs 
for acute myeloid leukaemia with six cancers, 
for chronic myeloid leukaemia two cancers, for 
myelodysplastic syndrome with four cancers, and for 
myeloproliferative neoplasm with four cancers. The 
RRs for both reciprocal associations of acute myeloid 
leukaemia and haematological cancers and anal cancer 
were high.
We assessed RRs for second primary cancers after 
different subtypes of myeloproliferative neoplasm. The 
overall RRs for diagnosis of any second primary cancer 
after polycythaemia vera, essential thrombocythaemia, 
myelofibrosis, or myeloproliferative neoplasm (not 
otherwise specified) were 1·34 (95% CI 1·25–1·43), 1·39 
(1·27–1·54), 1·88 (1·64–2·17), and 1·50 (1·28–1·76), 
respectively, compared with risk of any first primary 
cancer (table 6). Polycythaemia vera as a first primary 
cancer was associated with increased risk for 11 second 
primary cancers; essential thrombocythemia and 
Acute myeloid leukemia Chronic myeloid leukemia Myelodysplastic syndrome Myeloproliferative neoplasms
N RR (95%CI) N RR (95%CI) N RR (95%CI) N RR (95%CI)
Upper aerodigestive 
tract
39 1·42* (1·03–1·94) 11 1·14 (0·63–2·07) 16 1·48 (0·91–2·42) 28 0·81 (0·56–1·17)
Oesophagus 2 0·71 (0·18–2·85) 2 2·26 (0·57–9·05) 2 1·69 (0·42–6·75) 0 ··
Stomach 21 0·85 (0·56–1·31) 10 1·18 (0·64–2·20) 11 1·45(0·8–2·62) 24 0·97 (0·65–1·45)
Small intestine 5 1·51 (0·63–3·63) 2 1·90 (0·47–7·59) 4 2·37 (0·89–6·32) 6 1·38 (0·62–3·07)
Colorectum 135 1·21* (1·02–1·44) 40 1·15 (0·84–1·58) 73 1·25 (0·99–1·58) 115 0·80 (0·67–0·96)
Anus 7 3·88† (1·85–8·13) 0 ·· 0 ·· 1 0·39 0·05–2·77)
Liver 4 0·65 (0·24–1·73) 3 1·61 (0·52–4·99) 1 0·41 (0·06–2·93) 0 ··
Pancreas 1 0·17 (0·02–1·18) 1 0·53 (0·07–3·74) 2 1·04 (0·26–4·17) 3 0·53 (0·17–1·64)
Nose 3 1·66 (0·53–5·14) 0 ·· 0 ·· 2 0·92 (0·23–3·66)
Lung 26 1·16 (0·79–1·70) 9 1·28 (0·66–2·46) 18 1·79* (1·13–2·85) 20 0·74 (0·48–1·15)
Breast 249 1·43† (1·26–1·62) 74 1·29* (1·03–1·63) 83 0·94 (0·76–1·17) 219 0·92 (0·80–1·05)
Cervix 42 1·61‡ (1·19–2·18) 5 0·49 (0·20–1·18) 9 0·96 (0·50–1·85) 15 0·46* (0·28–0·76)
Endometrium 72 1·41‡ (1·11–1·77) 25 1·53* (1·03–2·27) 32 1·16 (0·82–1·64) 50 0·72* (0·54–0·95)
Ovary 61 2·55† (1·98–3·28) 8 0·97 (0·49–1·95) 16 1·58 (0·97–2·59) 25 0·83 (0·56–1·23)
Other female genital 9 1·92* (1·00–3·69) 1 0·64 (0·09–4·52) 3 1·49 (0·48–4·61) 4 0·69 (0·26–1·85)
Prostate 219 1·31† (1·15–1·50) 73 1·57† (1·24–1·98) 159 1·45† (1·23–1·70) 244 1·06 (0·93–1·20)
Testis 14 2·58† (1·53–4·37) 6 2·60* (1·17–5·79) 5 2·50* (1·04–6·02) 7 0·98 (0·47–2·06)
Kidney 33 1·35 (0·96–1·90) 14 1·76* (1·04–2·97) 14 1·28 (0·76–2·17) 51 1·68† (1·28–2·21)
Bladder 85 1·57† (1·27–1·95) 23 1·38 (0·91–2·08) 44 1·49‡ (1·11–2·01) 85 1·16 (0·94–1·44)
Melanoma 38 0·95 (0·69–1·30) 16 1·24 (0·76–2·02) 29 1·20 (0·83–1·73) 86 1·45† (1·17–1·79)
Skin SCC 45 1·09 (0·81–1·46) 19 1·51 (0·96–2·38) 49 1·92† (1·45–2·55) 82 1·45† (1·17–1·81)
Nervous system 36 1·39* (1·00–1·92) 4 0·45 (0·17–1·20) 12 1·03 (0·58–1·81) 36 1·09 (0·79–1·52)
Thyroid gland 20 1·72* (1·11–2·67) 5 1·23 (0·51–2·97) 9 1·80 (0·94–3·47) 39 2·61† (1·91–3·58)
Endocrine gland 25 0·99 (0·67–1·47) 10 1·26 (0·68–2·35) 13 0·94 (0·54–1·62) 52 1·48‡ (1·13–1·95)
Bone 5 2·44* (1·02–5·87) 1 1·32 (0·19–9·34) 1 1·26 (0·18–8·98) 2 0·82 (0·20–3·26)
Connective tissue 10 1·55 (0·83–2·88) 1 0·45 (0·06–3·21) 5 1·68 (0·70–4·03) 13 1·55 (0·90–2·66)
Non–Hodgkin 
lymphoma
119 5·16† (4·31–6·19) 10 1·42 (0·76–2·46) 76 6·03† (4·80–7·57) 34 1·10 (0·79–1·55)
Hodgkin’s 
lymphoma
35 7·69† (5·52–10·72) 1 0·55 (0·08–3·89) 15 10·04† (6·05–16·68) 8 1·50 (0·75–2·99)
Myeloma 76 8·71† (6·95–10·91) 1 0·36 (0·05–2·58) 35 9·45† (6·77–13·19) 10 0·96 (0·51–1·78)
Cancer of unknown 
primary
11 1·16 (0·64–2·10) 3 1·00 (0·32–3·09) 5 1·37 (0·57–3·28) 7 0·68 (0·32–1·43)
All 1463 1·57† (1·48–1·65) 380 1·26† (1·13–1·40) 750 1·54† (1·42–1·67) 1280 1·02 (0·96–1·08)
N=frequency. RR=relative risk. SCC=squamous cell carcinoma. *Statistical significance at 5%. †Statistical significance at 0·1%. ‡Statistical significance at 1%.
Table 5: Relative risk of myeloid cancer after first primary cancer
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myelo fibrosis were both associated with increased risk of 
seven secondary primary cancers; and myeloproliferative 
neoplasm (not otherwise specified) was associated with 
increased risk of developing second primary cancer at 
nine cancer sites relative to the background rates for 
these cancers. All myeloproliferative neoplasms were 
associated with an increased risk of developing skin 
squamous cell carcinoma as a second primary cancer, 
with the greatest risk after myelofibrosis (RR 3·71, 95% CI 
2·27–6·05). Relative risks of nervous system cancer 
were increased after polycythaemia vera, essential 
thrombocythaemia, and myelofibrosis; risks of non-
Hodgkin lymphoma were increased after polycythaemia 
vera, myelofibrosis, and myeloproliferative neoplasm (not 
otherwise specified). Risk of other female genital cancers 
(RR 3·31, 95% CI 1·38–7·96) was increased only in 
patients who had had essential thrombocythaemia. Risk 
of Hodgkin’s lymphoma (RR 12·26, 95% CI 3·95–18·03) 
was increased in patients with previous myelofibrosis.
We assessed the risk of myelioproliferative neoplasms 
as second primary cancers after other cancers 
(appendix p 7). With the exception of kidney and thyroid 
cancers, no other cancers were observed to have increased 
risk throughout most of the subtypes of myeloproliferative 
neoplasms. We noted we noted reciprocal associations 
confirming increased bi- directional risk for six unique 
cancer-myeloproliferative neoplasm pairs (melanoma, 
kidney, and connective tissue cancer paired with 
Polycythemia vera Essential thrombocythemia Myelofibrosis Myeloproliferative neoplasm 
(not otherwise specified)
N RR (95% CI) N RR (95% CI) N RR (95% CI) N RR (95% CI)
Upper aerodigestive 
tract
20 1·44 (0·93–2·23) 10 1·66 (0·89–3·09) 5 2·82* (1·17–6·77) 7 3·27† (1·56–6·85)
Oesophagus 10 1·41 (0·76–2·62) 5 1·61 (0·67–3·88) 0 ·· 0 ··
Stomach 32 1·01 (0·71–1·43) 12 1·26 (0·71–2·21) 1 0·30 (0·04–2·11) 1 0·32 (0·04–2·26)
Small intestine 3 1·02 (0·33–3·15) 4 2·93* (1·10–7·81) 0 ·· 2 4·09* (1·02–16·38)
Colorectum 77 0·89 (0·71–1·12) 38 0·94 (0·68–1·29) 13 1·19 (0·69–2·05) 24 1·66* (1·11–2·48)
Anus 4 2·93* (1·10–7·81) 1 1·34 (0·19–9·53) 0 ·· 0 ··
Liver 30 1·29 (0·90–1·84) 6 0·70 (0·31–1·56) 5 1·78 (0·74–4·27) 4 1·39 (0·52–3·70)
Pancreas 23 1·02 (0·68–1·54) 13 1·40 (0·79–2·46) 4 1·45 (0·54–3·86) 6 2·04 (0·91–4·53)
Nose 3 2·94 (0·95–9·12) 1 2·42 (0·34–17·23) 0 ·· 1 6·99 (0·98–49·70)
Lung 86 1·57‡ (1·27–1·94) 32 1·31 (0·93–1·86) 6 0·85 (0·38–1·89) 15 1·73* (1·04–2·87)
Breast 76 1·23 (0·98–1·54) 39 1·18 (0·86–1·61) 6 0·85 (0·38–1·90) 9 0·83 (0·43–1·60)
Cervix 3 0·66 (0·21–2·03) 3 1·59 (0·51–4·94) 0 ·· 2 3·54 (0·88–14·14)
Endometrium 15 1·04 (0·63–1·73) 9 1·18 (0·62–2·27) 1 0·59 (0·08–4·19) 1 0·40 (0·06–2·81)
Ovary 12 1·03 (0·58–1·81) 5 1·05 (0·44–2·51) 1 0·76 (0·11–5·43) 3 2·03 (0·65–6·29)
Other female genitals 0 ·· 5 3·31 (1·38–7·96) 0 ·· 0 ··
Prostate 156 1·25† (1·07–1·47) 63 1·15 (0·90–1·48) 21 1·11 (0·72–1·70) 20 0·87 (0·65–1·35)
Testis 1 1·97 (0·28–13·99) 0 ·· 0 ·· 0 ··
Kidney 46 2·51‡ (1·87–3·36) 18 2·44‡ (1·52–3·93) 5 2·22 (0·92–5·33) 4 1·65 (0·62–4·38)
Bladder 49 1·53† (1·15–2·02) 19 1·24 (0·79–1·94) 2 0·49 (0·12–1·94) 6 1·07 (0·48–2·38)
Melanoma 37 2·27‡ (1·65–3·14) 23 2·26‡ (1·50–3·40) 4 1·66 (0·62–4·42) 6 1·60 (0·72–3·56)
Skin SCC 73 2·19‡ (1·74–2·76) 52 2·57‡ (1·95–3·38) 16 3·71‡ (2·27–6·05) 26 3·45‡ (2·35–5·06)
Nervous system 29 2·17‡ (1·51–3·13) 16 2·63‡ (1·61–4·29) 6 3·29†  (1·48–7·32) 4 1·88 (0·71–5·01)
Thyroid gland 2 0·58 (0·15–2·34) 3 1·94 (0·63–6·02) 0 ·· 3 5·59† (1·80–17·33)
Endocrine gland 26 3·49‡  (2·38–5·13) 11 3·10‡  (1·72–5·61) 1 0·94 (0·13–6·70) 3 2·41 (0·78–7·49)
Bone 2 3·27 (0·82–13·08) 0 ·· 1 12·31* (1·73–87·47) 0 ··
Connective tissue 6 1·70 (0·76–3·79) 2 1·25 (0·31–5·01) 2 4·35* (1·09–17·38) 1 1·75 (0·25–12·40)
non-Hodgkin 
lymphoma
31 1·59* (1·12–2·26) 14 1·42 (0·84–2·40) 7 2·64* (1·26–5·53) 12 3·29‡ (1·87–5·80)
Hodgkin’s lymphoma 3 1·55 (0·50–4·80) 2 2·74 (0·69–10·98) 3 12·26† (3·95–38·03) 2 8·19* (2·05–32·76)
Multiple myeloma 17 1·64* (1·02–2·64) 0 ·· 0 ·· 2 1·21 (0·30–4·84)
Cancer of unknown 
primary
33 1·30 (0·93–1·83) 13 1·16 (0·67–2·00) 6 1·86 (0·84–4·14) 8 1·98* (1·09–3·95)
All 916 1·34‡ (1·25–1·43) 422 1·39‡ (1·27–1·54) 118 1·88‡ (1·64–2·17) 173 1·50‡ (1·28–1·76)
N=frequency. RR=relative risk. SCC=squamous cell carcinoma. *Statistical significance at 5%. †Statistical significance at 1%. ‡Statistical significance at 0·1%. 
Table 6: Relative risk of second primary cancers among patients with different subtypes of myeloproliferative neoplas
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polycythemia vera; squamous cell carcinoma of skin 
paired with myelofibrosis; and small intestine cancer and 
non-Hodgkin lymphoma paired with myeloproliferative 
neoplasm (not otherwise specified).
Discussion
To address a paucity of data regarding the development 
of second primary cancers after myeloproliferative neo-
plasms, we used data from the Swedish Cancer Registry 
to analyse all myeloid cancers and second primary 
cancers in Sweden, and myeloid cancers diagnosed as 
second primary cancers after any non-leukaemic first 
cancer, between 1958 and 2015. Our analysis provides 
further evidence that survivorship from a myeloid cancer 
is associated with a statistically significant relative risk of 
a second primary cancer. We showed that the increased 
relative risk is not confined to any one myeloid cancer, 
and is also increased after myelodysplastic syndrome. 
The relative risk of upper aerodigestive tract cancer, skin 
squamous cell carcinoma, and non-Hodgkin lymphoma 
were the major second primary cancers after previous 
acute myeloid leukaemia, chronic myeloid leukaemia, 
myelodysplastic syndrome, and myeloproliferative 
neoplasm. Our results thus provide new systematically 
analysed information on the risk of diverse types of 
second primary cancers, and validate and expand 
previous observations.9,10,12–15
A major strength of our study, as compared with other 
analyses, is the avoidance of ascertainment bias in patient 
selection by using a registry that includes data from the 
entire Swedish population, with high proportions of case 
registration and long-term follow up. To the best of our 
knowledge, this is the first study to apply systematic bi-
directional analysis for second primary cancer after 
myeloid cancer and myeloid cancer as second primary 
cancer. We used data from the largest population of 
myeloid neoplasms yet published.9
The limitations include unavailability of some myeloid 
neoplasms before year 1993 and no information on 
treatment, in addition to the inherent weaknesses of 
observational studies in deducing disease causation. 
Although the coverage of the Swedish Cancer Registry is 
high, it might not be equally high for some newly 
established diagnostic categories, such as myelodysplastic 
syndrome. Other factors that are difficult to control for 
are reporting practices of second primary cancers.
Treatment-related side-effects are generally considered 
to be the cause of many second primary cancers following 
treatment for a myeloid cancer.20 However, such a 
mechanism is unlikely to be the sole cause for all second 
primary cancers; there might be several mechanisms 
underlying the increased risk of a second primary cancer 
risk in patients who have had myeloid cancer. Although 
treatment for the myeloid cancers is heterogeneous and 
has changed over time, many patients—and certainly 
those in our cohort diagnosed before the year 2000—are 
likely to have received one or more types of cytoreductive 
treatment during their disease course.4,21 Hydroxyurea has 
been used as first line cytoreductive treatment for 
myeloproliferative neoplasm in many patients. An 
increased risk of non-melanoma skin cancer during 
hydroxyurea treatment has been reported, and people 
have hypothesised that hydroxyurea could act as a 
photosensitiser and thus, in combination with ultraviolet 
radiation exposure, increase the risk of skin squamous 
cell carcinoma.22 However, this mechanism is not likely to 
be the cause of a myeloproliferative cancer that develops 
after a first primary skin squamous cell carcinoma 
because this type of skin cancer is usually treated by 
surgery. By contrast, side-effects of other chemotherapeutic 
agents such as anthracyclines might have contributed to 
the increased risk of second primary cancers after myeloid 
neoplasia, such as in cases of lung and upper aerodigestive 
tract cancers. We showed a possible increase in relative 
risk in cases with upper aerodigestive tract cancer after 
chronic myeloid leukaemia diagnosed between 2001 and 
2015 as compared with the earlier study periods, which a 
previous small Swedish study suggested might have been 
associated with the use of tyrosine kinase inhibitors.10 We 
noted that testicular cancer was associated with an 
increased risk of acute myeloid leukaemia, chronic 
myeloid leukaemia, and myelodysplastic syndrome. 
Testicular cancer is treated with radiotherapy and a 
combination of drugs that damage DNA, such as 
bleomycin, etoposide, and cisplatin, which might be an 
explanation for the increased risk of second myeloid 
neoplasia.23
In this study, myeloid neoplasms were associated with 
all haematological cancers that might have had acquired 
immune dysfunction due to cytotoxic treatment or bone 
marrow transplantation as an underlying mechanism.24 
Inherited mechanisms might also contribute to the 
development of myeloid neoplasms through master 
regulators of haemopoiesis, including transcriptional 
regulators of critical steps in cell development such as 
STAT5, CEBPα, PU.1, and CITED2, among others.25 
Their expression is controlled at the genetic or epigenetic 
level, and aberrations in their expression might have 
pleiotropic effects on several cell lineages. For example, 
loss of the genetic regulator GATA-2 has been shown to 
suppress haemopoiesis and contribute to immuno- 
deficiency.26 Changes in the expression of other epigenetic 
regulators, such as IDH, TET2, and BCAT1 genes, might 
have similar effects.27 Given that many cancer 
susceptibility genes have pleiotropic effects it is plausible 
that the risk of a second primary cancer is influenced by 
inherited genetic factors, either through high penetrance 
alleles or co-inheritance of multiple common risk 
variants. Patients with myeloid neoplasia have an 
increased risk of non-haematological cancers prior to 
their diagnosis of myeloproliferative neoplasm, and 
first-degree relatives of patients with myeloproliferative 
cancer have an increased risk of myeloproliferative 
neoplasms and chronic lymphocytic leukaemia—as well 
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as melanoma and brain cancer—which is consistent 
with germline susceptibility to myeloproliferative and 
other cancers.28,29 Although risks of other cancers in 
families of patients with myeloid neoplasia are yet to be 
established, common genetic variants of TERT associated 
with risk of myeloproliferative neoplasia have also been 
shown to influence glioma and other cancers.30 Familial 
risks might also be a contributing factor. We have 
previously published the results of a study of discordant 
associations between all common cancers using data 
from the Swedish Family-Cancer Database, and shown 
that discordant familial risks do exist but RRs are small, 
in the order of 1·1–1·2 for most cancer pairs.31
On the other hand, because myeloid diseases and their 
treatment can be associated with immunosuppression, 
this raises the possibility that impaired tumour 
immunosurveillance could play a part in the development 
of second primary cancers in patients with previous 
myeloid cancer.24 The contribution of immune dysfunction 
in these cancers might be compounded by germline 
susceptibility. For example, germline mutations in GATA2 
have been reported to contribute to immune deficiency in 
haematological cancers, including familial myelodysplastic 
syndrome and acute myeloid leukaemia.32 We have 
provided evidence of bi-directional associations between 
myeloid cancers and lymphomas, and between 
lymphomas and skin squamous cell carcinoma, kidney 
cancer, and bladder cancer. Increased risk of second 
primary cancer in patients with myeloid cancer is probably 
multifactorial. A combination of cytoreductive treatment, 
genetic predisposition, and immune-related effects might 
all contribute to an increased cancer risk in survivors of 
myeloid cancers.
In conclusion, we have provided a comprehensive 
analysis of cancer risks associated with myeloid cancers 
using observational data from a comprehensive cancer 
registry. We propose putative mechanisms that might 
contribute to these associations, such as immune 
disturbances acting together with cytotoxic and genetic 
effects. Future studies are clearly warranted to investigate 
such potential mechanisms in detail—for example, by 
assessing immune competence as a predictor of second 
primary cancer, and the effects of immunotherapy on 
the risk of second primary cancers. Our findings 
substantiate the well-known risks of developing second 
primary cancers after surviving each of the myeloid 
cancers, and help inform the long-term management of 
patients successfully treated for these tumours, who 
should be monitored for the occurrence of second 
primary cancers.
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